Ogeda SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Ogeda SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014353
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ogeda SA (Ogeda), formerly Euroscreen SA is a biotechnology company that develops small molecule drugs targeting G-protein coupled receptors. The company discovers and develops drugs that treats hormone-dependent pathologies in women’s health. It also develops drugs to treat neurodegenerative diseases and other exploratory programs for various metabolic diseases such as diabetes and obesity. Ogeda offers G-protein-coupled receptors customized screening, cell lines and other services for biotech and pharmaceutical companies. The company conducts various pre-clinical drug discovery programs in endocrine, CNS and inflammatory disorders. The company partners with various pharma companies to develop its products. Ogeda is headquartered in Gosselies, Belgium.

Ogeda SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Ogeda SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Ogeda SA, Medical Devices Deals, 2011 to YTD 2017 9
Ogeda SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ogeda SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Euroscreen Raises USD17.8 Million in Series B Financing Round 11
Euroscreen Raises US$13 Million In Series A Financing 13
Licensing Agreements 14
Euroscreen Enters into Licensing Agreement with Merck 14
Euroscreen Enters Into Licensing Agreement With Ortho-McNeil-Janssen 15
Acquisition 16
Astellas Pharma Acquires Ogeda for up to USD852 Million 16
Ogeda SA – Key Competitors 17
Ogeda SA – Key Employees 18
Ogeda SA – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Mar 04, 2016: Euroscreen Strengthens its Management Team 20
Product Approvals 21
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials 21
Clinical Trials 22
Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes 22
Other Significant Developments 23
Oct 19, 2016: Euroscreen announces name change to Ogeda 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Ogeda SA, Pharmaceuticals & Healthcare, Key Facts 2
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Ogeda SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Ogeda SA, Deals By Therapy Area, 2011 to YTD 2017 8
Ogeda SA, Medical Devices Deals, 2011 to YTD 2017 9
Ogeda SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Euroscreen Raises USD17.8 Million in Series B Financing Round 11
Euroscreen Raises US$13 Million In Series A Financing 13
Euroscreen Enters into Licensing Agreement with Merck 14
Euroscreen Enters Into Licensing Agreement With Ortho-McNeil-Janssen 15
Astellas Pharma Acquires Ogeda for up to USD852 Million 16
Ogeda SA, Key Competitors 17
Ogeda SA, Key Employees 18
Ogeda SA, Other Locations 19

★海外企業調査レポート[Ogeda SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Loblaw Companies Ltd (L):企業の財務・戦略的SWOT分析
    Loblaw Companies Ltd (L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Interface Biologics Inc:製品パイプライン分析
    Summary Interface Biologics Inc (IBI) is a developer transformative biomedical polymer technology. The company offers anti-thrombogenic and combination drug delivery devices. Its blood contacting medical devices uses Endexo technology address problems related to thrombosis. IBI’s technologies includ …
  • Nishat Mills Ltd:企業の戦略・SWOT・財務分析
    Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report Summary Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Oldenburgische Landesbank AG:企業の戦略・SWOT・財務分析
    Oldenburgische Landesbank AG - Strategy, SWOT and Corporate Finance Report Summary Oldenburgische Landesbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Polynt SpA:企業の戦略的SWOT分析
    Polynt SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Stingray Digital Group Inc.:企業のM&A・事業提携・投資動向
    Stingray Digital Group Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stingray Digital Group Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Vivus, Inc.:企業の戦略・SWOT・財務分析
    Vivus, Inc. - Strategy, SWOT and Corporate Finance Report Summary Vivus, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Grupo Juste SAQF:製薬・医療:M&Aディール及び事業提携情報
    Summary Grupo Juste SAQF (Juste) is a developer and distributor of proprietary medicines and active pharmaceutical ingredients. The company offers oral and injectable radiological contrast media; diatrizoic acid, iothalamic acid, iohexol, iopamidol, iodixanol, MRI contrast agents, dihexazin, and oth …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Euro India Fresh Foods Ltd (EIFFL):企業の財務・戦略的SWOT分析
    Euro India Fresh Foods Ltd (EIFFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Protokinetix Inc (PKTX):製薬・医療:M&Aディール及び事業提携情報
    Summary ProtoKinetix Inc (ProtoKinetix) is a biotechnology company that develops solutions for cell survival and health. The company develops anti-aging glycopeptides used to protect cell lines including hela cells, neonatal fibroblasts, adult fibroblast, human neuronal stem cells, CD34+ cells and k …
  • Bellvitge Biomedical Research Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center that offers health care development solutions. The center conducts clinical and basic research for developing treatments and techniques to improve health care. It offers its research work in the fields of neuro …
  • Allscripts Healthcare Solutions Inc (MDRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Allscripts Healthcare Solutions Inc (Allscripts), formerly Allscripts-Misys Healthcare Solutions, Inc., is a provider of healthcare information technology solutions. The company’s major solutions include Electronic Health Records (EHR), Financial Management Solutions, Population Health Manag …
  • NetSol Technologies, Inc. (NTWK):企業の財務・戦略的SWOT分析
    NetSol Technologies, Inc. (NTWK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Atomstroyexport:企業の戦略的SWOT分析
    Atomstroyexport - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Insperity Inc (NSP)
    Insperity Inc (NSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Sejal Glass Limited (SEZAL):企業の財務・戦略的SWOT分析
    Sejal Glass Limited (SEZAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Boralex Inc (BLX):電力:M&Aディール及び事業提携情報
    Summary Boralex Inc (Boralex) is a renewable energy company. It develops, builds, and operates renewable energy power facilities. The company’s asset portfolio includes wind, hydro, thermal, and solar projects. Boralex also has interests in various projects under development stages. Under long-term …
  • Axonics Modulation Technologies Inc (AXNX):医療機器:M&Aディール及び事業提携情報
    Summary Axonics Modulation Technologies Inc (Axonics) is an independent medical device company that develops and commercializes implantable neuromodulation technology for the treatment of urinary and bowel dysfunction. The company’s Sacral Neuromodulation System (r-SNM) is designed for the treatment …
  • Otonomy Inc (OTIC):企業の財務・戦略的SWOT分析
    Otonomy Inc (OTIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆